vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and AMERICAN SUPERCONDUCTOR CORP (AMSC). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $74.5M, roughly 1.9× AMERICAN SUPERCONDUCTOR CORP). AMERICAN SUPERCONDUCTOR CORP runs the higher net margin — 158.1% vs 35.5%, a 122.6% gap on every dollar of revenue. On growth, AMERICAN SUPERCONDUCTOR CORP posted the faster year-over-year revenue change (21.4% vs 18.4%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $2.4M). Over the past eight quarters, AMERICAN SUPERCONDUCTOR CORP's revenue compounded faster (33.2% CAGR vs 30.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Anglo American plc is a British multinational mining company with headquarters in London, England. It is the world's largest producer of platinum, representing approximately 40 percent of global output, as well as being a major producer of diamonds, copper, nickel, iron ore, polyhalite and steelmaking coal. The company has operations in Africa, Asia, Australia, Europe, North America and South America.
ADMA vs AMSC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $74.5M |
| Net Profit | $49.4M | $117.8M |
| Gross Margin | 63.8% | 30.7% |
| Operating Margin | 45.1% | 4.5% |
| Net Margin | 35.5% | 158.1% |
| Revenue YoY | 18.4% | 21.4% |
| Net Profit YoY | -55.9% | 4679.1% |
| EPS (diluted) | $0.20 | $2.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $74.5M | ||
| Q3 25 | $134.2M | $65.9M | ||
| Q2 25 | $122.0M | $72.4M | ||
| Q1 25 | $114.8M | $66.7M | ||
| Q4 24 | $117.5M | $61.4M | ||
| Q3 24 | $119.8M | $54.5M | ||
| Q2 24 | $107.2M | $40.3M | ||
| Q1 24 | $81.9M | $42.0M |
| Q4 25 | $49.4M | $117.8M | ||
| Q3 25 | $36.4M | $4.8M | ||
| Q2 25 | $34.2M | $6.7M | ||
| Q1 25 | $26.9M | $1.2M | ||
| Q4 24 | $111.9M | $2.5M | ||
| Q3 24 | $35.9M | $4.9M | ||
| Q2 24 | $32.1M | $-2.5M | ||
| Q1 24 | $17.8M | $-1.6M |
| Q4 25 | 63.8% | 30.7% | ||
| Q3 25 | 56.3% | 31.0% | ||
| Q2 25 | 55.1% | 33.8% | ||
| Q1 25 | 53.2% | 26.5% | ||
| Q4 24 | 53.9% | 26.6% | ||
| Q3 24 | 49.8% | 28.7% | ||
| Q2 24 | 53.6% | 30.3% | ||
| Q1 24 | 47.8% | 24.8% |
| Q4 25 | 45.1% | 4.5% | ||
| Q3 25 | 38.0% | 4.5% | ||
| Q2 25 | 35.1% | 7.8% | ||
| Q1 25 | 30.4% | 2.5% | ||
| Q4 24 | 32.6% | 2.1% | ||
| Q3 24 | 33.1% | -1.4% | ||
| Q2 24 | 36.6% | -8.2% | ||
| Q1 24 | 26.7% | -5.3% |
| Q4 25 | 35.5% | 158.1% | ||
| Q3 25 | 27.1% | 7.2% | ||
| Q2 25 | 28.1% | 9.3% | ||
| Q1 25 | 23.4% | 1.8% | ||
| Q4 24 | 95.2% | 4.0% | ||
| Q3 24 | 30.0% | 9.0% | ||
| Q2 24 | 29.9% | -6.3% | ||
| Q1 24 | 21.7% | -3.8% |
| Q4 25 | $0.20 | $2.62 | ||
| Q3 25 | $0.15 | $0.11 | ||
| Q2 25 | $0.14 | $0.17 | ||
| Q1 25 | $0.11 | $0.04 | ||
| Q4 24 | $0.45 | $0.06 | ||
| Q3 24 | $0.15 | $0.13 | ||
| Q2 24 | $0.13 | $-0.07 | ||
| Q1 24 | $0.08 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $141.1M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $536.8M |
| Total Assets | $624.2M | $719.5M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $141.1M | ||
| Q3 25 | $61.4M | $212.9M | ||
| Q2 25 | $90.3M | $207.9M | ||
| Q1 25 | $71.6M | $79.5M | ||
| Q4 24 | $103.1M | $75.2M | ||
| Q3 24 | $86.7M | $72.1M | ||
| Q2 24 | $88.2M | $93.5M | ||
| Q1 24 | $45.3M | $90.5M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $536.8M | ||
| Q3 25 | $431.2M | $342.2M | ||
| Q2 25 | $398.3M | $333.1M | ||
| Q1 25 | $373.4M | $197.1M | ||
| Q4 24 | $349.0M | $192.7M | ||
| Q3 24 | $231.9M | $187.0M | ||
| Q2 24 | $188.3M | $143.3M | ||
| Q1 24 | $153.7M | $144.6M |
| Q4 25 | $624.2M | $719.5M | ||
| Q3 25 | $568.7M | $445.6M | ||
| Q2 25 | $558.4M | $452.8M | ||
| Q1 25 | $510.6M | $310.5M | ||
| Q4 24 | $488.7M | $310.3M | ||
| Q3 24 | $390.6M | $298.4M | ||
| Q2 24 | $376.4M | $240.1M | ||
| Q1 24 | $350.9M | $232.8M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $3.2M |
| Free Cash FlowOCF − Capex | $34.6M | $2.4M |
| FCF MarginFCF / Revenue | 24.8% | 3.2% |
| Capex IntensityCapex / Revenue | 0.8% | 1.2% |
| Cash ConversionOCF / Net Profit | 0.72× | 0.03× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $16.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $3.2M | ||
| Q3 25 | $13.3M | $6.5M | ||
| Q2 25 | $21.1M | $4.1M | ||
| Q1 25 | $-19.7M | $6.3M | ||
| Q4 24 | $50.2M | $5.9M | ||
| Q3 24 | $25.0M | $12.7M | ||
| Q2 24 | $45.6M | $3.4M | ||
| Q1 24 | $-2.2M | $2.2M |
| Q4 25 | $34.6M | $2.4M | ||
| Q3 25 | $-1.1M | $5.1M | ||
| Q2 25 | $18.7M | $3.3M | ||
| Q1 25 | $-24.4M | $5.3M | ||
| Q4 24 | $47.5M | $5.3M | ||
| Q3 24 | $24.0M | $12.1M | ||
| Q2 24 | $43.6M | $3.1M | ||
| Q1 24 | $-4.6M | $1.9M |
| Q4 25 | 24.8% | 3.2% | ||
| Q3 25 | -0.8% | 7.7% | ||
| Q2 25 | 15.3% | 4.6% | ||
| Q1 25 | -21.2% | 7.9% | ||
| Q4 24 | 40.4% | 8.7% | ||
| Q3 24 | 20.0% | 22.3% | ||
| Q2 24 | 40.7% | 7.8% | ||
| Q1 24 | -5.6% | 4.6% |
| Q4 25 | 0.8% | 1.2% | ||
| Q3 25 | 10.7% | 2.1% | ||
| Q2 25 | 2.0% | 1.1% | ||
| Q1 25 | 4.1% | 1.6% | ||
| Q4 24 | 2.3% | 0.9% | ||
| Q3 24 | 0.9% | 1.1% | ||
| Q2 24 | 1.9% | 0.7% | ||
| Q1 24 | 2.9% | 0.7% |
| Q4 25 | 0.72× | 0.03× | ||
| Q3 25 | 0.36× | 1.37× | ||
| Q2 25 | 0.62× | 0.61× | ||
| Q1 25 | -0.73× | 5.22× | ||
| Q4 24 | 0.45× | 2.38× | ||
| Q3 24 | 0.70× | 2.60× | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
AMSC
| Equipment And Systems | $56.0M | 75% |
| Megatran | $14.1M | 19% |
| Comtrafo Industria De Transformadores Eletricos SA | $4.6M | 6% |
